Rating Rationale
November 25, 2020 | Mumbai
NGL Fine Chem Limited
Ratings upgraded to 'CRISIL BBB+/Stable/CRISIL A2'
 
Rating Action
Total Bank Loan Facilities RatedRs.50.89 Crore
Long Term RatingCRISIL BBB+/Stable (Upgraded from 'CRISIL BBB/Positive')
Short Term RatingCRISIL A2 (Upgraded from 'CRISIL A3+')
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has upgraded its ratings on the bank facilities of NGL Fine Chem Limited (NFC) to 'CRISIL BBB+/Stable/CRISIL A2' from 'CRISIL BBB/Positive/CRISIL A3+'.
 
The upgrade reflects CRISIL belief that NFC business risk profile will continue to improve, driven by healthy revenue growth of more than 10% per fiscal and a stable operating margin of around 19%. The growth should be supported by the recently completed capacity expansion and an established market position in manufacturing of veterinary active pharmaceutical ingredients (APIs), backed by a healthy demand. Revenue growth and profitability should remain healthy in fiscal 2021 since NFC could revive its operations quite quickly during lockdown and thus was proven to be a more reliable source for its customers. Consequently, revenue and operating margin have been strong, at Rs 111 crore and 31%, respectively, for the first half of fiscal 2021 as against revenues and operating margin of Rs 78 crore and 16.5%, respectively, for the first half of fiscal 2020.
 
The ratings continue to reflect extensive experience of the promoters in animal health API industry, established and diversified customer base and NFC's healthy financial risk profile. These strengths are partially offset by vulnerability of profitability to volatility in raw material prices, high product concentration risk with major presence in animal health API and large working capital requirement.

Analytical Approach

For arriving at the ratings, CRISIL has combined the financial and business risk profiles of NFC and its wholly-owned subsidiary, Macrotech Polychem Pvt Ltd (MPPL). That is because both these companies, together referred to herein as NFC, have a common management and strong operational and financial links.

Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description
Strengths: 
* Extensive experience of management in animal health API industry: Incorporated in 1981, NFC primarily manufactures veterinary pharmaceutical APIs and intermediates catering to the anti-protozoal and anthelmintic therapeutic segments. The company's directors, Mr. Rajesh Lawande and Mr. Rahul Nachane, have extensive experience of over two decades in the manufacturing of animal health APIs.
 
* Established and diversified customer base: NFC derives 20-25% of its sales from the domestic market and the remaining from export sales to countries in Europe, Asia Pacific, Middle East and Latin America. NFC's customer base is diversified with the top five customers accounting for ~25% of total sales in FY2019 and FY2020 respectively. The promoters' experience of over two decades, their understanding of market dynamics and healthy relationships with suppliers and customers have helped establish a strong presence in the highly fragmented bulk drugs industry.
 
* Healthy financial risk profile: Financial risk profile is likely to remain healthy supported by moderate debt levels and healthy accretion to reserve. Networth increased to Rs 98.60 crore as on March 31, 2020, from Rs 90.50 crore a year ago, with gearing and total outside liabilities to tangible networth ratio comfortable at 0.30 time and 0.55 time, respectively. Debt protection metrics were strong, with net cash accrual to total debt and interest coverage ratios of 0.54 time and 9.50 times, respectively, for fiscal 2020.
 
Weaknesses:
* Vulnerability of profitability to volatility in raw material prices: NFC's major raw materials are intermediates (N-2 and N-3 level intermediates) and solvents used for manufacturing the APIs. Given the elevated inventory levels, the company's operating profitability remains exposed to the adverse movements in the raw materials prices that cannot be adequately passed onto the customers.
 
* High product concentration risk with major presence in animal health API: NFC primarily manufactures various veterinary APIs, which account for ~90% of the total annual sales, while the rest are derived from intermediates, formulations and human APIs. Despite having more than 22 products in the product portfolio, the company revenues have remained concentrated with the top three products (namely Diminazene, Clorsulon and Buparavaquone) which contributed ~48% of its total sales in FY2019 and FY2020.
 
* Large working capital requirement: NFC's working capital intensity has historically remained high due to increased receivables and elevated inventory levels. Gross current assets (GCA) excluding cash are at 160 days as on March 31, 2020, led by receivables and inventory of 64 days and 80 days, respectively. Working capital is partially funded through credit from suppliers (114 days) and working capital bank lines. Operations are expected to remain working capital intensive going ahead with GCA in range of 160-170 days.
Liquidity Adequate

Liquidity should continue to remain adequate, supported by the surplus cash accrual and cushion in bank lines. Cash accrual is expected to be at Rs 29-33 crore per annum over medium term, sufficient to meet the yearly debt obligation of Rs 3-6 crore. Bank limit utilisation has been moderate and averaged 51% during the 12 months through June 2020 despite the large working capital requirement. Unencumbered marketable securities were about Rs 14 crore as on 30th September 2020. CRISIL has also taken into account the Reserve Bank of India-approved moratorium on debt obligation related to term loan for the six months ended August 31, 2020. The company is planning to undertake capex of Rs 60 crore; the funding pattern is not yet finalized for same; however NFC has sufficient headroom for availing debt for this capex. Net cash accrual, unutilised bank limit, and cash and equivalent will be sufficient to cover incremental working capital requirement, debt obligation and capex over the medium term.

Outlook: Stable

NFC should continue to benefit from extensive experience of promoters and established customer relationships.

Rating Sensitivity factors
Upward factors
* Sustained revenue growth of over 10% per fiscal backed by successful ramp-up of operations from planned capacity expansion, while maintaining operating margin
* Meaningful diversification in product profiles
* Significant and sustained improvement in working capital cycle
 
Downward factors
* Sustained decline in operating profitability to below 16%
* Higher-than-expected increase in working capital requirement; larger-than-expected, debt-funded capex or acquisition or dividend pay-out; weakening the financial risk profile and liquidity
About the Company

NFC, incorporated in 1981, manufactures human and veterinary bulk drugs, intermediates, and formulations. It primarily deals in animal healthcare products such as antiprotozoal, anthelmintics, and growth promoters. The administrative office is in Mumbai and manufacturing facilities are in Tarapur and Navi Mumbai in Maharashtra. Mr Rahul Nachane and Mr Rajesh Lawande manage the business. In May 2019, NFC acquired 100% equity shareholding in MPPL, which manufactures pharmaceutical intermediates.

Key Financial Indicators consolidated
Particulars Unit 2020 2019
Revenue Rs crore 151.7 153.2
Profit after tax (PAT) Rs crore 8.34 20.1
PAT margin % 5.50 13.14
Adjusted debt/adjusted networth Times 0.29 0.30
Interest coverage Times 9.54 15.47

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings' complexity levels are assigned to various types of financial instruments. The CRISIL Ratings' complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL Ratings' complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of allotment Coupon
rate (%)
Maturity date Issue size
(Rs cr)
Complexity levels Rating assigned with outlook
NA Cash Credit NA NA NA 18.5 NA CRISIL BBB+/Stable
NA Foreign Exchange Facility NA NA NA 0.19 NA CRISIL A2
NA Letter of Credit NA NA NA 6.8 NA CRISIL A2
NA Pre Shipment Credit NA NA NA 1.5 NA CRISIL A2
NA Term Loan NA NA Oct-2022 23.9 NA CRISIL BBB+/Stable
 
Annexure - List of entities consolidated
Names of entities consolidated Extent of consolidation Rationale for consolidation
NFC Full Common management and strong operational and financial link
MPPL Full Common management and strong operational and financial link
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  44.09  CRISIL BBB+/Stable/ CRISIL A2      10-09-19  CRISIL BBB/Positive/ CRISIL A3+  05-07-18  CRISIL BBB/Stable/ CRISIL A3+  06-09-17  CRISIL BBB/Stable/ CRISIL A3+  CRISIL BBB/Stable/ CRISIL A3+ 
Non Fund-based Bank Facilities  LT/ST  6.80  CRISIL A2      10-09-19  CRISIL A3+  05-07-18  CRISIL A3+  06-09-17  CRISIL A3+  CRISIL A3+ 
All amounts are in Rs.Cr.
 
Annexure - Details of Bank Lenders & Facilities
Facility Name of Lender Amount (Rs.Crore) Rating
Cash Credit HDFC Bank Limited 18.5 CRISIL BBB+/Stable
Foreign Exchange Facility HDFC Bank Limited 0.19 CRISIL A2
Letter of Credit HDFC Bank Limited 6.8 CRISIL A2
Pre Shipment Credit HDFC Bank Limited 1.5 CRISIL A2
Term Loan HDFC Bank Limited 23.9 CRISIL BBB+/Stable

This Annexure has been updated on 2-Sep-2021 in line with the lender-wise facility details as on 2-Aug-2021 received from the rated entity.

Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for rating short term debt
CRISILs Criteria for Consolidation

Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
 naireen.ahmed@crisil.com

Rahul Subrato Kumar Guha
Director
CRISIL Ratings Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Jumana Badshah
Associate Director
CRISIL Ratings Limited
D:+91 22 3342 8324
Jumana.Badshah@crisil.com


Vishal More
Rating Analyst
CRISIL Ratings Limited
B:+91 22 3342 3000
Vishal.More@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ("CRISIL Ratings") is a wholly-owned subsidiary of CRISIL Limited ("CRISIL"). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 




About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale (each a "Report") that is provided by CRISIL Ratings Limited  (hereinafter referred to as "CRISIL Ratings") . For the avoidance of doubt, the term "Report" includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. Rating by CRISIL Ratings contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way. CRISIL Ratings or its associates may have other commercial transactions with the company/entity.

Neither CRISIL Ratings nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, "CRISIL Ratings Parties") guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Ratings Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL RATINGS' PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL Rating's public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: http://www.crisil.com/ratings/highlightedpolicy.html

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL Ratings you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings Limited is a wholly owned subsidiary of CRISIL Limited.

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011 to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratiings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: www.crisil.com/ratings/credit-rating-scale.html